Sildenafil--for treatment of preeclampsia and intrauterine growth restriction
Abstract
Pre-eclampsia and intrauterine growth restriction (IUGR) are responsible for approximately 15-20% of serious maternal and neonatal diseases. These complications are related to very early anomalies of the uteroplacental circulation, accompanied, at least secondarily, by thromboxane-prostacyclin-related imbalances. Studies have failed to show a beneficial effect of betamimetics and calcium channel blockers for the treatment of IUGR. Sildenafil citrate, a type 5-specific phosphodiesterase inhibitor, augments the vasodilatory effects of NO by preventing the degradation of cGMP There is a selective effect of Sildenafil on the uteroplacental circulation. Sildenafil improves uterine artery blood flow.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.